Arrowhead Pharmaceuticals’ Post

In obesity clinical trials, the typically used weight loss endpoints in kg or % of body weight give limited insights regarding drug efficacy and body composition changes. Integrating MRI-based measures of body and muscle composition will give more information about the source of the weight loss and other effects of the drug. Read more here: https://lnkd.in/dhayBgZw #clinicaltrials #obesity #weightloss

Are you attending the American Diabetes Association’s 84th Scientific Sessions? Don’t miss our interactive symposium, "Striking a Balance: The Role of Glucagon Agonism to Improve Obesity and Metabolic Care." 📅 Date: Sunday, June 23, 2024 ⏰ Time: 7:00 PM - 8:30 PM ET Learn from two renowned obesity experts as they share cutting-edge insights and practice-changing data on novel therapeutic targets like glucagon agonism. This is a unique opportunity to enhance your clinical practice with the latest advancements in obesity treatment. https://bit.ly/4bq5Ovk

Child & adult obesity, Role of GLP-1 ANALOUGES ( Liraglutide / semaglutide) in management of DM-T2 & obesity. Effect of SGLT-2 inhibitors could be future drug of choice for DM-T2 Management. Benifits of using SGLT-2 inhibitors in cardiac and renal compromise patients ( Cana/Dapa/Empa - Gliflozin)

Understanding the underlying pathophysiology of obesity and diabetes, including the development of insulin resistance, is critical for diabesity treatment. Read our new blog to better understand how ideal therapeutic targets for diabesity address shared underlying mechanisms of both conditions. https://ow.ly/p8Ge50R4NLx

📊 New study by Bliddal et al. in the NEJM reveals the effects of GLP-1 agonists on obesity & osteoarthritis: 📉 GLP1 group lost an avg. of 10.5% more weight than placebo at week 68 (p<0.001). 🦵 Knee pain improved by 14.1 points on the WOMAC Pain Score vs. placebo (p<0.001). #GLP1 #obesitymanagement #osteoarthritis #weightloss

Exciting findings reveal Tirzepatide's future potential. New research shows a significant reduction in Diabetic Peripheral Neuropathy (DPN) risk over 2 years compared to insulin and other therapies, highlighting dual benefits in diabetes and obesity management with potential neuroprotective effects. This suggests broader implications beyond traditional diabetes management. Link: tinyurl.com/5xx9d3fr #DiabetesResearch #Neuroprotection #Tirzepatide"

https://lnkd.in/e-Xyeimx   This article perfectly summarizes the scientific importance of the work we’re doing at Mineralys. Along with #hypertension, the #obesity epidemic is driving dysregulated aldosterone production that contributes to #CKD, heart failure and multiple other cardiorenal diseases.   Lorundrostat is our highly selective aldosterone synthase inhibitor, which demonstrated enhanced efficacy in the patients with an elevated BMI. While currently in pivotal trials for uncontrolled and resistant hypertension, it represents a pipeline of broad #cardiorenal disease opportunities in the future.  #businessdevelopment #lifesciencesindustry

#ICYMI we recently shared positive top-line results from our Phase 1 clinical trial of an investigational oral #GLP-1R agonist in healthy adults with #obesity or overweight.  These findings represent important progress in our ongoing efforts to explore innovative treatments for obesity. We are encouraged by the potential of our approach and remain focused on advancing therapies that could positively impact the lives of those affected by obesity. Check out this article from Citeline Scrip for more insights: https://lnkd.in/e7e_nWMB or read our press release for details https://lnkd.in/e6VXMJ5U

A breakthrough weight-loss pill is emerging as potentially more effective than Ozempic, marking a significant advancement in obesity treatment. This innovation offers hope for more effective weight management solutions. #WeightLossInnovation #HealthTech https://lnkd.in/d9jPa66H

👉 Tirzepatide improves hepatic transaminases and fat content. 👉 Its effect on the parameters of hepatic fibrosis has not been proven and is inconsistent. 👉 The drug has reasonable hepatic safety, with a safety profile comparable to other treatment options and placebo. Our meta-analysis has been published in Diabetes, Obesity and Metabolism, a prestigious journal with 2023 Journal Impact Factor (Clarivate) 5.4 https://lnkd.in/gJmEVwKz